Business Context and Reporting Period
Company: Rocket Pharmaceuticals, Inc. (RCKT)
Filing Type: Form 8-K (Current Report)
Report Date: February 26, 2026
Reporting Period: Quarter and fiscal year ended December 31, 2025
This filing serves as a notification that the Company has announced financial results for the specified period. The detailed financial data is contained in a press release furnished as Exhibit 99.1, which is not deemed "filed" for purposes of Section 18 of the Exchange Act.
Key Financial Metrics
The provided text does not contain specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are referenced as being included in the attached press release (Exhibit 99.1) but are not present in the body of this Form 8-K.
Material Changes
The filing text does not provide specific details regarding material changes versus the prior comparable period. It only confirms the announcement of results for the quarter and fiscal year ended December 31, 2025.
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release for management commentary but does not include the text of that commentary.
Guidance and Outlook: No forward-looking guidance or outlook is provided in this document.
Risks and Contingencies: No specific risks or contingencies are detailed in this filing text.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated February 26, 2026) for actual financial figures, as they are not included in this 8-K summary.
- Verify the specific revenue and net loss figures for the quarter and full year ended December 31, 2025.
- Check the press release for any updates on clinical trial progress or regulatory milestones, which are typical drivers for biopharmaceutical companies.
- Confirm cash position and burn rate details to assess runway, as these are critical for pre-revenue or early-stage pharmaceutical firms.